# Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma

> **NCT05708300** · — · RECRUITING · sponsor: **Aristotle University Of Thessaloniki** · enrollment: 57 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps
- Asthma

## Interventions

- **DRUG:** Mepolizumab 100 MG [Nucala]

## Key facts

- **NCT ID:** NCT05708300
- **Lead sponsor:** Aristotle University Of Thessaloniki
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-23
- **Primary completion:** 2026-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05708300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05708300, "Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05708300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*